Transport characteristics of fexofenadine in the Caco-2 cell model
- PMID: 15359574
- DOI: 10.1023/b:pham.0000036913.90332.b1
Transport characteristics of fexofenadine in the Caco-2 cell model
Abstract
Purpose: To investigate the membrane transport mechanisms of fexofenadine in the Caco-2 model.
Methods: Transport studies were performed in Caco-2 cell monolayers 21-25 days after seeding. The apparent permeability (Papp) of fexofenadine was determined in the concentration range 10-1000 microM in the basolateral-to-apical (b-a) and 50-1000 microM in the apical-to-basolateral (a-b) direction. The concentration-dependent effects of various inhibitors of P-glycoprotein (P-gp) (GF120918, ketoconazole, verapamil, erythromycin), multidrug resistant associated protein (MRP) (indomethacin, probenecid), and organic anion transporting polypeptide (OATP) (rifamycin SV) on the bidirectional transport of 150 microM fexofenadine were also examined.
Results: Fexofenadine displayed polarized transport, with the Pappb-a being 28- to 85-fold higher than the Papp(a-b). The Papp(a-b) was independent of the concentration applied, whereas Pappb-a decreased with increasing concentration (Vmax = 5.21 nmol cm(-2)s(-1) and K(M) = 150 microM), suggesting saturation of an apical efflux transporter. All four P-gp inhibitors had a strong, concentration-dependent effect on the Papp of fexofenadine in both directions, with GF 120918 being the most specific among them. The IC50 of verapamil was 8.44 microM on the P-gp-mediated secretion of fexofenadine. The inhibitors of OATP or MRP appeared not to affect the Papp(a-b) of fexofenadine in the Caco-2 model.
Conclusions: This study clearly indicates that P-gp was the main transport protein of fexofenadine in the Caco-2 model. Even though P-gp was completely inhibited, fexofenadine was predicted to have a low fraction dose absorbed in humans due to poor intestinal permeability, and low passive diffusion seems to be the major absorption mechanism.
Similar articles
-
Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.Mol Pharm. 2011 Oct 3;8(5):1677-86. doi: 10.1021/mp200026v. Epub 2011 Aug 5. Mol Pharm. 2011. PMID: 21780830
-
Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.J Pharm Pharm Sci. 2011;14(3):325-35. doi: 10.18433/j3501w. J Pharm Pharm Sci. 2011. PMID: 21824448
-
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. AAPS J. 2009. PMID: 19319690 Free PMC article.
-
An update on the clinical pharmacokinetics of fexofenadine enantiomers.Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):429-434. doi: 10.1080/17425255.2018.1459565. Epub 2018 Apr 11. Expert Opin Drug Metab Toxicol. 2018. PMID: 29635947 Review.
-
[Determinants of the stereoselective pharmacokinetics of fexofenadine].Yakugaku Zasshi. 2015;135(3):473-81. doi: 10.1248/yakushi.14-00218. Yakugaku Zasshi. 2015. PMID: 25759055 Review. Japanese.
Cited by
-
Fexofenadine hydrochloride in the treatment of allergic disease: a review.J Asthma Allergy. 2008 Sep 19;1:19-29. doi: 10.2147/jaa.s3092. J Asthma Allergy. 2008. PMID: 21436982 Free PMC article.
-
Renal Drug Transporters and Drug Interactions.Clin Pharmacokinet. 2017 Aug;56(8):825-892. doi: 10.1007/s40262-017-0506-8. Clin Pharmacokinet. 2017. PMID: 28210973 Review.
-
A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect".J Clin Pharmacol. 2013 Sep;53(9):982-90. doi: 10.1002/jcph.136. Epub 2013 Jul 23. J Clin Pharmacol. 2013. PMID: 23878024 Free PMC article. Clinical Trial.
-
Coexistence of passive and carrier-mediated processes in drug transport.Nat Rev Drug Discov. 2010 Aug;9(8):597-614. doi: 10.1038/nrd3187. Nat Rev Drug Discov. 2010. PMID: 20671764 Review.
-
Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.Pharm Res. 2008 Nov;25(11):2601-12. doi: 10.1007/s11095-008-9678-0. Epub 2008 Jul 25. Pharm Res. 2008. PMID: 18654741
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information
Miscellaneous